KLHDC8B: A Potential Drug Target and Biomarker (G200942)

Target Name: KLHDC8B

NCBI ID: G200942

KLHDC8B

KLHDC8B: A Potential Drug Target and Biomarker

KLHDC8B (Kinesin-light chain protein subunit B) is a protein that is expressed in various tissues and cells in the human body. It is a key component of the kinesin system, which is a protein structure that is found in the cytosol of eukaryotic cells. The kinesin system plays a crucial role in the movement of various cellular structures, including chromosomes, organelles, and vesicles within the cytosol.

Recent studies have identified KLHDC8B as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

One of the key reasons for the potential of KLHDC8B as a drug target is its unique structure. KLHDC8B is a 21-kDa protein that consists of 115 amino acid residues. It has a characteristic Rossmann-fold, which is a type of structural protein that is composed of a specific arrangement of amino acids. This fold is unique to KLHDC8B and is not found in any other protein.

KLHDC8B's structure is also important for its function. It plays a critical role in the movement of chromosomes in the cytosol. Chromosomes are complex structures that contain DNA, RNA, and proteins. They are found in the nucleus of eukaryotic cells and are responsible for the transmission of genetic information from the parents to the offspring.

KLHDC8B is one of the proteins that is involved in the movement of chromosomes in the cytosol. It is essential for the proper separation of chromosomes during cell division, which is critical for the proper functioning of the cell.

Another reason why KLHDC8B is a promising drug target is its involvement in various diseases. Several studies have shown that KLHDC8B is overexpressed or under expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, a study by researchers at the University of California, San Diego found that KLHDC8B was overexpressed in various cancer tissues. The researchers suggested that KLHDC8B may be a useful biomarker for cancer and that its expression may also be a potential therapeutic target.

Another study by researchers at the University of California, Davis found that KLHDC8B was under expressed in the brains of individuals with neurodegenerative diseases. The researchers suggested that KLHDC8B may be a potential therapeutic target for these diseases.

Finally, a study by researchers at the University of Cambridge found that KLHDC8B was overexpressed in various autoimmune tissues. The researchers suggested that KLHDC8B may be a potential therapeutic target for autoimmune disorders.

In conclusion, KLHDC8B is a protein that is expressed in various tissues and cells in the human body. Its unique structure and function make it an attractive target for researchers to study and develop new treatments for various diseases. Its potential as a drug target and biomarker make it an important area of research to study. Further studies are needed to fully understand its role in the kinesin system and its potential as a therapeutic target.

Protein Name: Kelch Domain Containing 8B

Functions: Involved in pinching off the separated nuclei at the cleavage furrow and in cytokinesis (PubMed:20107318). Required for mitotic integrity and maintenance of chromosomal stability. Protects cells against mitotic errors, centrosomal amplification, micronucleus formation and aneuploidy. Plays a key role of midbody function involving abscission of the daughter cells during cytokinesis and appropriate chromosomal and nuclear segregation into the daughter cells (PubMed:22988245, PubMed:23713010)

The "KLHDC8B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC8B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets